KUVAN SAPROPTERIN DIHYDROCHLORIDE Tablets or Powder Instructions
- June 3, 2024
- KUVAN
Table of Contents
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES
SAPROPTERIN
Generic | Brand | HICL | GCN | Medi-Span | Exception/Other |
---|
SAPROPTERIN
DIHYDROCHLORIDE| KUVAN, JAVYGTOR, SAPROPTERIN DIHYDROCHLORIDE| 35266| | GPI-10
(3090856510)| FDB: ROUTE = ORAL
GUIDELINES FOR USE
INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
- Does the patient have a diagnosis of hyperphenylalaninemia (HPA) due to tetrahydrobiopterin
(BH4)-responsive phenylketonuria (PKU) and meet ALL of the following criteria?
The patient is 1 month of age or older
The patient follows a phenylalanine-restricted diet
The patient is NOT concurrently using Palynziq (penalize-pqpz)
If yes, approve for 1 month by HICL or GPI-10.
If no, do not approve.
INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis.
Please use these definitions if the particular text you need to use does not
already have a definition(s) in it.
Our guideline named SAPROPTERIN (Kuvan, Javygtor) requires the following
rule(s) be met for approval:
A. You have hyperphenylalaninemia (HPA) due to tetrahydrobiopterin
(BH4)-responsive phenylketonuria (PKU) (you have high levels of a type of
amino acid phenylalanine and it can be lowered with certain supplement
tetrahydrobiopterin)
B. You are 1 month of age or older
C. You follow a phenylalanine-restricted diet
D. You are NOT using Palynziq (penalize-pqpz) at the same time
Our guideline named SAPROPTERIN (Kuvan, Javygtor) requires the following
rule(s) be met for approval:
A. You have hyperphenylalaninemia (HPA) due to tetrahydrobiopterin
(BH4)-responsive phenylketonuria (PKU) (you have high levels of a type of
amino acid phenylalanine and it can be lowered with certain supplement
tetrahydrobiopterin)
B. You are 1 month of age or older
C. You follow a phenylalanine-restricted diet
D. You are NOT using Palynziq (penalize-pqpz) at the same time
CONTINUED ON THE NEXT PAGE
RENEWAL CRITERIA
- Does the patient have a diagnosis of hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4)-responsive phenylketonuria (PKU) and meet ALL of the following criteria?
• The patient experienced a 30% decrease in blood phenylalanine from baseline after taking sapropterin
• The patient follows a phenylalanine-restricted diet
• The patient is NOT concurrently using Palynziq (penalize-pqpz)
If yes, approve for 12 months by HICL or GPI-10. If no, do not approve.
RENEWAL DENIAL TEXT : *Some terms are already pre-defined in parenthesis.
Please use these definitions if the particular text you need to use does not
already have a definition(s) in it.
Our guideline named SAPROPTERIN (Kuvan, Javygtor) requires the following
rule(s) be met for renewal:
A. You have hyperphenylalaninemia (HPA) due to tetrahydrobiopterin
(BH4)-responsive phenylketonuria (PKU) (you have high levels of a type of
amino acid phenylalanine and it can be lowered with certain supplement
tetrahydrobiopterin)
B. You experienced at least a 30 percent decrease in blood phenylalanine from
baseline after taking sapropterin
C. You continue to follow a phenylalanine-restricted diet
D. You are NOT using Palynziq (penalize-pqpz) at the same time
Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have
information showing you [INSERT UNMET CRITERIA]. This is why your request is
denied. Please work with your doctor to use a different medication or get us
more information if it will allow us to approve this request.
RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Sapropterin (Kuvan, Javygtor).
REFERENCES
Kuvan [Prescribing Information]. Novato, CA: BioMarin Pharmaceutical Inc., February 2021.
Library | Commercial | NSA |
---|---|---|
Yes | Yes | No |
Part D Effective: N/A
Commercial Effective: 10/01/22
Created: 01/08
Client Approval: 09/22
P&T Approval: 04/22
Copyright © 2022 MedImpact Healthcare Systems, Inc. All rights reserved. This
document is proprietary to MedImpact.
MedImpact maintains the sole and exclusive ownership, right, title, and
interest in and to this document.
Revised: 9/16/2022
Read User Manual Online (PDF format)
Read User Manual Online (PDF format) >>